Total Funding
8
Total FundingVenture - Series Unknown raised
Growth Score in past quarter
pts
Heat Score 8 in past quarter
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
Aldexa Therapeutics develops treatments for the dry form of age-related macular degeneration eye disease.
About the Company
Aldexa Therapeutics, Inc. develops treatments for the dry form of age-related macular degeneration eye disease that may lead to blindness. It activities include the development of drugs to inhibit the formation of toxic metabolites that accumulate in the back of the eye. Aldexa Therapeutics, Inc. was formerly known as Neuron Systems, Inc. The
company was incorporated in 2004 and is based in Burlington, Massachusetts. The company changed its name to Aldeyra Therapeutics, Inc. on March 17, 2014. Aldeyra held an initial public offering on May 7, 2014.
